| Theme | The frontline of Crohn's disease treatment | |
|---|---|---|
| Title | Therapeutic options for patients with loss of response to anti-TNF-α agents | |
| Publish Date | 2016/03 | |
| Author | Makoto Tanaka | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| Author | Kazuhiko Uchiyama | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| Author | Tomohisa Takagi | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| Author | Yuji Naito | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| [ Summary ] | Anti-TNF-α agents play a central role in the treatment for Crohn's disease (CD). Because of high efficacy of these therapeutic agents, the number of patients treated with anti-TNF-α antibodies for long term is increasing. However, the number of patients showing loss of response (LOR) has also increased. The solution to this problem might be either a change in the therapeutic regimen (dose escalation or switching to anti-TNF-α agents, additional treatment with immunomodulator and granulocyte/monocyte apheresis) or surgical treatment. Because various mechanisms of LOR have been reported, individual approaches for each patient are required. | |